Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 6/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CCR1 | P32246 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853580 | 0.90 | MLNR (0.52) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL1995197 | 0.89 | MLNR (0.63) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL2856291 | 0.89 | MLNR (0.75) | MLNRKMT2AMEN1NPC1RAB9A | |
| SCHEMBL3659038 | 0.88 | MLNR (0.53) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL2856258 | 0.88 | MLNR (0.53) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL2849453 | 0.88 | MLNR (0.73) | MLNRKCNH2CCR1KMT2APTGDR2 | |
| SCHEMBL2851975 | 0.86 | MLNR (0.74) | MLNRKCNH2PTGDR2MGLL | |
| SCHEMBL3656919 | 0.85 | MLNR (0.50) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL2849498 | 0.85 | MLNR (0.51) | MLNRKCNH2CCR1KMT2AMEN1 | |
| SCHEMBL2853570 | 0.84 | MLNR (0.51) | MLNRCCR1FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| EP-2212299-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | Glaxo Group Limited (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009068552-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | MLNR 12/4885KCNH2 2812/4885CCR1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.